Yang, H.Y.; Park, K.S.; Shin, H.H.; Choi, J.H.; Seon, J.K. Preoperative Intravenous Ferric Carboxymaltose Improves Recovery from Anemia in Patients Undergoing Revision Joint Arthroplasty: A Randomized Controlled Trial. Preprints2023, 2023121984. https://doi.org/10.20944/preprints202312.1984.v1
APA Style
Yang, H.Y., Park, K.S., Shin, H.H., Choi, J.H., & Seon, J.K. (2023). Preoperative Intravenous Ferric Carboxymaltose Improves Recovery from Anemia in Patients Undergoing Revision Joint Arthroplasty: A Randomized Controlled Trial. Preprints. https://doi.org/10.20944/preprints202312.1984.v1
Chicago/Turabian Style
Yang, H.Y., Ji Hoon Choi and Jong Keun Seon. 2023 "Preoperative Intravenous Ferric Carboxymaltose Improves Recovery from Anemia in Patients Undergoing Revision Joint Arthroplasty: A Randomized Controlled Trial" Preprints. https://doi.org/10.20944/preprints202312.1984.v1
Abstract
(1) Background: Ferric carboxymaltose (FCM) is an intravenous (IV) high-dose iron that is effective in the treatment of iron deficiency anemia. This study was to determine if preoperative IV FCM administration could improve recovery from postoperative anemia in patients undergoing revision total joint arthroplasty. (2) Methods: This prospective randomized controlled study analyzed 82 patients undergoing revision total joint arthroplasty during a single hospitalization. Patients in the iron group (n = 41) were administered 1000 mg of IV FCM two weeks preoperatively, while those in the control group (n = 41) were not. Moreover, patients with anemia defined as a preoperative suboptimal Hb concentration <13.0 g/dl were compared according to IV FCM administration. The absolute Hb levels and changes in Hb levels, iron profiles, transfusion rate, and EuroQOL 5-dimension (EQ-5D) scores were compared. (3) Results: There were no significant differences in recovery of Hb levels at each timepoint between the two groups; however, the changes in Hb levels from baseline to four weeks postoperatively showed marginally significant differences favoring the iron group (p = 0.052). However, for preoperatively anemic patients, the change in hemoglobin (Hb) levels between baseline and four weeks postoperatively was significantly better in the iron group than in the control group (iron group [n = 26], −0.3 ± 0.7 g/dL vs. control group [n = 27], −0.9 ± 0.8 g/dL; p = 0.040), although the absolute Hb levels, transfusion rates, and patient quality of life were comparable (all p > 0.05). The iron group showed improved iron metabolite levels including serum ferritin and transferrin saturation four weeks postoperatively, and no adverse events associated with IV FCM administration occurred in either group. (4) Conclusions: Preoperative IV FCM in anemic individuals undergoing revision joint arthroplasty was effective in accelerating recovery from surgery-related anemia by improving Hb levels without any adverse events, despite similar actual Hb levels between the groups. Our findings are clinically relevant and can facilitate determination of the suitability of IV FCM as a safe and reliable protocol for iron supplementation for anemia correction.
Keywords
revision joint arthroplasty; iron supplementation; ferric carboxymaltose; hemoglobin; iron metabolism
Subject
Medicine and Pharmacology, Orthopedics and Sports Medicine
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
